Loading organizations...
§ Private Profile · 610 W Germantown Pike, Plymouth Meeting, PA 19462, USA
Medtech company developing non-invasive devices using sensors and machine learning to estimate intracardiac pressures for heart failure management.
Based in Helsingborg, Sweden, Acorai is a medical technology company developing a non-invasive handheld device that estimates intracardiac pressures for heart failure management. The clinical-stage hardware utilizes a combination of acoustic, seismic, visual, and electrocardiographic sensors paired with proprietary machine learning algorithms to monitor the pulmonary artery pressure without requiring invasive surgical catheterization procedures. Targeted primarily at hospitals, clinics, and cardiologists, the monitoring system received Breakthrough Device Designation from the US FDA in August 2023 to support its ongoing global clinical validation studies. The medical device startup has secured over $8 million in total financing to date, which includes a $4.5 million seed funding round closed in January 2024 with participation from Solardis Health Ventures, KHP Ventures, and Capital A Partners. Acorai was founded in 2019 by Filip Peters, Jakob Gelberg, and Kasper Bourdette.
Acorai has raised $18.1M across 2 funding rounds.
Acorai has raised $18.1M in total across 2 funding rounds.
Acorai has raised $18.1M across 2 funding rounds. Most recently, it raised $5.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2024 | $5M Seed | Solardis Health Ventures | Bayer, Carma Fund, Cedars Sinai, KHP Ventures, Mayo Clinic | Announced |
| Nov 8, 2023 | $13.2M Grant | European Innovation Council | — | Announced |
Acorai has raised $18.1M in total across 2 funding rounds.
Acorai's investors include Solardis Health Ventures, Bayer, Carma Fund, Cedars-Sinai, KHP Ventures, Mayo Clinic, European Innovation Council.
Acorai is a Swedish health tech startup founded in 2019 that develops the Acorai Heart Monitor, a non-invasive handheld device for estimating intracardiac pressures in heart failure patients using seismic, acoustic, visual, and ECG sensors combined with machine learning.[1][2][5] It primarily serves healthcare professionals in hospitals to improve heart failure management for over 60 million patients worldwide by enabling frequent, trend-based monitoring without invasive procedures like catheterization, which only reaches about 10% of patients.[1][2] The company has raised $23.8M total, including a recent $4.5M round six months ago, and has demonstrated clinical accuracy matching gold standards in a 200-patient feasibility study, positioning it for commercialization with low regulatory risk.[1][3]
Acorai was co-founded in 2019 in Helsingborg, Sweden, by Filip Peters (CEO) and Jakob Gelberg (CTO), who drew inspiration from non-medical industries like oil and gas for non-invasive pressure sensing via seismic and acoustic technologies, adapting them for cardiac diagnostics.[2][4] The initial concept targeted remote at-home monitoring for preventive care, but pivoted to in-hospital use after feedback from cardiologists and nurses highlighted unmet needs in managing admitted heart failure patients, offering a superior value proposition.[2] Early traction came from a 200-patient feasibility study validating accuracy against invasive methods, alongside partnerships with top institutions like Cedars-Sinai, Mayo Clinic, and Royal Brompton Hospital.[1][5]
Acorai rides the wave of AI-driven, non-invasive diagnostics in medtech, addressing the global heart failure crisis affecting 64 million patients amid rising hospitalizations and readmissions.[1][2] Timing aligns with post-pandemic demands for scalable hospital tools that reduce invasive procedures (used in only 10% of cases) and enable personalized treatment, fueled by machine learning advancements and data from leading hospitals.[2][5] Market tailwinds include aging populations, healthcare cost pressures, and regulatory fast-tracks for low-risk devices; competitors like Bodyport (scale-based monitoring) and Datos Health (AI workflows) focus on remote or broader RPM, but Acorai's in-hospital precision via novel sensor stacks carves a niche in acute care.[1] It influences the ecosystem by partnering with top U.S./U.K. centers, potentially setting standards for multi-sensor cardiac tech and lowering barriers for similar innovations.[5]
Acorai's momentum—oversubscribed seed, clinical wins, and elite partnerships—positions it for U.S. market entry and broader adoption in heart failure care, with next steps likely including FDA clearance, expanded trials, and Series A funding.[1][2][3] Trends like AI-sensor integration and value-based care will propel growth, evolving its influence from hospital tool to ecosystem platform via data partnerships. As non-invasive monitoring disrupts invasive norms, Acorai could redefine scalable heart failure management, echoing its origins in overlooked in-hospital needs.[2][5]